Excellent Response to Adapted Low-Dose 177Lu-PSMA-617 PSMA Therapy in Renal Compromise Patient

被引:3
作者
Usmani, Sharjeel [1 ]
Al Kandari, Fareeda [1 ]
Alrekhais, Ibrahim [1 ]
N. Khalaf, Shatha [1 ]
Ahmed, Najeeb [2 ]
机构
[1] Kuwait Canc Control Ctr KCCC, Cottingham, England
[2] Castle Hill Hosp, Jack Brignall PET CT Ctr, Cottingham, England
关键词
Ga-68-PSMA PET/CT; Lu-177-PSMA-617; chronic kidney disease; prostate cancer; radionuclide therapy; RESISTANT PROSTATE-CANCER; RADIOLIGAND THERAPY;
D O I
10.1097/RLU.0000000000003912
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with 177Lu-PSMA-617 has shown promising results in patients with metastasized castration-resistant prostate cancer. We report a case of a 74-year-old man with metastatic prostate cancer with comorbidities of diabetes mellitus, hypertension, and chronic kidney disease. In order to minimize radiation burden to kidneys, a lower dose of 4 GBq of 177Lu-PSMA-617 was prescribed instead of the usual 6 to 7 GBq. There was significant decrease in prostate-specific antigen levels and symptoms. Renal profile remained stable. This case highlights that compromised renal function is not a definite contraindication to radionuclide therapy, and doses can be modified based on risk versus benefits. © 2021 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:E213 / E214
页数:2
相关论文
共 10 条
[1]   Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer [J].
Ahmadzadehfar, Hojjat ;
Eppard, Elisabeth ;
Kuerpig, Stefan ;
Fimmers, Rolf ;
Yordanova, Anna ;
Schlenkhoff, Carl Diedrich ;
Gaertner, Florian ;
Rogenhofer, Sebastian ;
Essler, Markus .
ONCOTARGET, 2016, 7 (11) :12477-12488
[2]   177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy [J].
Baum, Richard P. ;
Kulkarni, Harshad R. ;
Schuchardt, Christiane ;
Singh, Aviral ;
Wirtz, Martina ;
Wiessalla, Stefan ;
Schottelius, Margret ;
Mueller, Dirk ;
Klette, Ingo ;
Wester, Hans-Juergen .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1006-1013
[3]   Renal outcomes of radioligand therapy: experience of 177lutetium-prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer [J].
Gallyamov, Marat ;
Meyrick, Danielle ;
Barley, Jerome ;
Lenzo, Nat .
CLINICAL KIDNEY JOURNAL, 2020, 13 (06) :1049-1055
[4]   [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study [J].
Hofman, Michael S. ;
Violet, John ;
Hicks, Rodney J. ;
Ferdinandus, Justin ;
Thang, Sue Ping ;
Akhurst, Tim ;
Iravani, Amir ;
Kong, Grace ;
Kumar, Aravind Ravi ;
Murphy, Declan G. ;
Eu, Peter ;
Jackson, Price ;
Scalzo, Mark ;
Williams, Scott G. ;
Sandhu, Shahneen .
LANCET ONCOLOGY, 2018, 19 (06) :825-833
[5]   Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney [J].
Norouzi, Ghazal ;
Aghdam, Ramin Akbarian ;
Hashemifard, Hamidreza ;
Pirayesh, Elahe .
CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) :483-484
[6]   Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq [J].
Rathke, Hendrik ;
Giesel, Frederik L. ;
Flechsig, Paul ;
Kopka, Klaus ;
Mier, Walter ;
Hohenfellner, Markus ;
Haberkorn, Uwe ;
Kratochwil, Clemens .
JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (03) :459-465
[7]   Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer [J].
Sartor, Oliver ;
de Bono, Johann ;
Chi, Kim N. ;
Fizazi, Karim ;
Herrmann, Ken ;
Rahbar, Kambiz ;
Tagawa, Scott T. ;
Nordquist, Luke T. ;
Vaishampayan, Nitin ;
El-Haddad, Ghassan ;
Park, Chandler H. ;
Beer, Tomasz M. ;
Armour, Alison ;
Perez-Contreras, Wendy J. ;
DeSilvio, Michelle ;
Kpamegan, Euloge ;
Gericke, Germo ;
Messmann, Richard A. ;
Morris, Michael J. ;
Krause, Bernd J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12) :1091-1103
[8]  
Silver DA, 1997, CLIN CANCER RES, V3, P81
[9]   Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis [J].
Yadav, Madhav Prasad ;
Ballal, Sanjana ;
Sahoo, Ranjit Kumar ;
Dwivedi, Sada Nand ;
Bal, Chandrasekhar .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2019, 213 (02) :275-285
[10]   177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney [J].
Zhang, Jingjing ;
Kulkarni, Harshad R. ;
Singh, Aviral ;
Schuchardt, Christiane ;
Niepsch, Karin ;
Langbein, Thomas ;
Baum, Richard P. .
JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (11) :1579-1586